# Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

> **NCT07079410** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Oral Squamous Cell Carcinoma (OSCC)
- Oropharyngeal Squamous Cell Carcinoma
- Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab+Cetuximab

## Key facts

- **NCT ID:** NCT07079410
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2027-07
- **Final completion:** 2029-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07079410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07079410, "Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07079410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*